title: Irinotecan compared with etoposide in combination with platinum in previously untreated extensive stage small cell lung cancer: An updated systemic review.
abstract: OBJECTIVE
  To compare the therapeutic effect of irinotecan/platinum (IP) and etoposide/platinum (EP) in treatment-naïve extensive small cell lung cancer patients.
  
  
  METHODS
  Systematic computerized searches of PubMed database and Chinese National Knowledge Infrastructure were performed. Summary odds ratio (OR) or hazard ratio (HR), and 95% confidence intervals (95% CI) were used to compare IP with EP in previously untreated small cell lung cancer patients.
  
  
  RESULTS
  A total of 10 randomized trials were included in the analyses. The result showed the patients treated with irinotecan combinations experienced longer overall survival than epotoside, the pooled HR was 0.85 (95% CI = 0.78-0.92). The pooled OR revealed that IP stated better objective overall response than EP regimens (OR = 1.10, 95% CI = 0.92-1.32). Treatment-related deaths were similar between the two groups.
  
  
  CONCLUSIONS
  IP regimens could be used as first-line treatment for extensive stage small cell lung cancer patients.
authors.affiliation: Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
authors.forename: Qinyong
authors.initials: Q
authors.lastname: Hu
authors.affiliation: Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
authors.forename: Hengbo
authors.initials: H
authors.lastname: Zhu
authors.affiliation: Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Yao
authors.affiliation: Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
authors.forename: Qibin
authors.initials: Q
authors.lastname: Song
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005047:Etoposide / Q000008:administration & dosage; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D010984:Platinum / Q000008:administration & dosage; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D002166:Camptothecin; D005047:Etoposide; D000077146:Irinotecan; D010984:Platinum